Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? - Wikidata - wikimedia - TriplyDB

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

http://www.wikidata.org/entity/Q27023707

about

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches Biosimilar: what it is not Clinical trials for authorized biosimilars in the European Union: a systematic review.An update on the clinical evidence that supports biosimilar approvals in Europe.

P2860

Q26740235-88918530-0782-4B9D-831E-4B43772A5EE5 Q28080832-8BA1FEFE-48A6-4083-B923-B7796D2D6741 Q28080880-78FF861E-1FDC-4F90-9841-4D0813016B30 Q37399588-1A438F4D-6293-4519-8A7E-DDC077BED6CE Q52343061-FF708469-F7E3-4E89-8AD6-048C19AB2B21

P2860

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

http://www.wikidata.org/entity/Q27023707

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@ast

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@en

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@nl

type

label

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@ast

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@en

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@nl

prefLabel

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@ast

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@en

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@nl

P1433

Q27023707-788807B7-DD72-4910-A882-3367F1C08A30

P1476

Q27023707-6D6751F2-BC9A-4DE9-91FC-B39B6ECE8BCE

P2093

Q27023707-149318BC-9072-4107-8496-F8034F151C9E

P2860

Q27023707-07D501D6-C6AF-4D2B-B975-2EBD153AE0B8

Q27023707-357E70C1-2110-4AC4-9021-482721396D18

Q27023707-3ED32806-42C6-428F-9013-FA0CECF07DEA

Q27023707-445E3067-8B12-48D3-90D5-84A62D0542BC

Q27023707-4BDF35C9-D0C2-40F7-A43B-478CE0B18FB0

Q27023707-61195B91-21FA-49B8-AD55-01E1B3F7502A

Q27023707-69911727-CD1F-41A0-BBFF-9223C85356FB

Q27023707-97AB9680-2192-4DED-9D27-B37A89978638

Q27023707-A4FC779C-25B9-4EC4-B635-9F3DB38CAFCC

Q27023707-B19FF848-BE6C-44E5-B369-BE0AAEA381B2

P304

Q27023707-E38C9BBB-1A76-4B34-8FA8-0437A72B2A9C

P31

Q27023707-75F7883E-3EF4-455A-9E99-D5CA886540D2

P3181

Q27023707-A4ACA518-159D-4864-ABBE-51AAF3FA136B

P356

Q27023707-69E3E547-4F3A-4E53-A77D-1AE26C228330

P407

Q27023707-156B6918-AC89-4C94-BF61-C0DED7735294

P433

Q27023707-2BB5FD05-3EDC-4FBB-910E-1D7E528492A5

P478

Q27023707-74E1B13A-01A1-4AAA-B996-9CB7E250527A

P577

Q27023707-C785F1AB-E70E-408F-A316-F5D88937584C

P5875

Q27023707-2F665D98-7FFE-4FCB-9636-E3D59159C2A1

P698

Q27023707-F7B397B3-FDC5-4DE0-BD35-601C046F4A27

P932

Q27023707-33619160-862D-4E5B-A50D-5CF7EF1DBC70

P3181

P356

J.1365-2125.2012.04323.X

P1433

British Journal of Clinical Pharmacology

P1476

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

@en

P2093

John B. Warren

http://www.w3.org/2001/XMLSchema#string

P2860

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al

Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation

Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate

Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.

Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI.

Sensitive studies with a significant dose-response curve for inhaled corticosteroids to investigate equivalent relative potency are feasible.

P304

7-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

353473

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1365-2125.2012.04323.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224938037

http://www.w3.org/2001/XMLSchema#string

P698

22574725

http://www.w3.org/2001/XMLSchema#string

P932

3555041

http://www.w3.org/2001/XMLSchema#string